Hematopoietic stem cell transplantation for MDS.

Publication Type:

Journal Article


Hematology/oncology clinics of North America, Volume 24, Issue 2, p.407-22 (2010)


2010, Aged, Aged, 80 and over, Blood Transfusion, Center-Authored Paper, Clinical Research Division, Combined Modality Therapy, Comorbidity, Enzyme Inhibitors, Graft vs Host Disease, hematopoietic stem cell transplantation, Humans, Iron Overload, Myelodysplastic Syndromes, Patient Selection, Prognosis, RECURRENCE, Remission Induction, Research Trials Office Core Facility - Biostatistics Service, Risk Assessment, Salvage Therapy, Severity of Illness Index, Shared Resources, Transplantation Conditioning, Treatment Outcome


Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for patients with myelodysplastic syndromes (MDS). However, as the majority of patients with MDS are in the seventh or eighth decade of life, conventional transplant regimens have been used only infrequently, and only with the development of reduced-intensity conditioning has transplantation been applied more broadly to older patients. Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be expected to be cured of their disease and survive long term. However, posttransplant relapse and graft-versus-host disease (GVHD) remain problems and further investigations are needed.